Yayın:
Poly(p‐phenylene) with Poly(ethylene glycol) Chains and Amino Groups as a Functional Platform for Controlled Drug Release and Radiotherapy

dc.contributor.authorGuler, Bahar
dc.contributor.authorAkbulut, Huseyin
dc.contributor.authorBarlas, Firat Baris
dc.contributor.authorGeyik, Caner
dc.contributor.authorDemirkol, Dilek Odaci
dc.contributor.authorSenisik, Ahmet Murat
dc.contributor.authorArican, Halil Armagan
dc.contributor.authorCoskunol, Hakan
dc.contributor.authorTimur, Suna
dc.contributor.authorYagci, Yusuf
dc.date.accessioned2026-01-24T21:48:23Z
dc.date.issued2016-01-21
dc.description.abstractConventional cancer treatments such as chemotherapy, radiotherapy, or combination of these two result in side effects, which lower the quality of life of the patients. To overcome problems with these methods, altering the drug properties by conjugating them to carrier polymers has emerged. Such polymeric carriers also hold the potential to make tumor cells more sensitive to radiation therapy. Herein, poly(p‐phenylene) (PPP) polymer with poly(ethylene glycol) (PEG) chains and primary amino groups (PPP‐NH2‐g‐PEG) is synthesized and conjugated with anticancer drug Doxorubicin (DOX). pH dependent drug release experiments are performed at pH 5.3 and pH 7.4, respectively. Cell viability studies on human cervix adenocarcinoma cells show that lower doses of DOX inhibit cell proliferation when conjugated with nontoxic doses of PPP‐NH2‐g‐PEG polymer. Additionally, PPP‐NH2‐g‐PEG/Cys/DOX bioconjugate significantly increases radiosensitive properties of DOX. It is possible to use lower doses of DOX when conjugated to PPP‐NH2‐g‐PEG in combination with radiotherapy. image
dc.description.urihttps://doi.org/10.1002/mabi.201500384
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/26797717
dc.description.urihttps://dx.doi.org/10.1002/mabi.201500384
dc.description.urihttps://hdl.handle.net/11454/52819
dc.identifier.doi10.1002/mabi.201500384
dc.identifier.eissn1616-5195
dc.identifier.endpage737
dc.identifier.issn1616-5187
dc.identifier.openairedoi_dedup___::27fc2ce170a9d13e614c3dd1f927d6d5
dc.identifier.orcid0000-0002-8382-2186
dc.identifier.orcid0000-0002-7954-1381
dc.identifier.orcid0000-0002-1981-7577
dc.identifier.startpage730
dc.identifier.urihttps://hdl.handle.net/11527/37827
dc.identifier.volume16
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofMacromolecular Bioscience
dc.rightsCLOSED
dc.sdg.typeGoal 3: Good Health and Well-being
dc.subjectDrug Carriers
dc.subjectCell Survival
dc.subjectPolymers
dc.subjectbioconjugation
dc.subjectUterine Cervical Neoplasms
dc.subjectAntineoplastic Agents
dc.subjectpoly(p-phenylene)s
dc.subjectPolyethylene Glycols
dc.subjectradiosensitivity
dc.subjectDoxorubicin
dc.subjectCell Line, Tumor
dc.subjectDelayed-Action Preparations
dc.subjectHumans
dc.subjectFemale
dc.subjectgraft copolymer
dc.subjectdrug release
dc.titlePoly(p‐phenylene) with Poly(ethylene glycol) Chains and Amino Groups as a Functional Platform for Controlled Drug Release and Radiotherapy
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyonlar